BridgeBio Oncology Therapeutics (BBOT) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, gaining 15.1% versus a loss of 71.8%. BridgeBio Oncology Therapeutics is the larger company by market cap ($274.2 million vs $266.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | IKT |
|---|---|---|
| Share price | $3.42 | $1.91 |
| Market cap | $274.20M | $266.51M |
| 1-day change | -0.58% | -1.55% |
| YTD return | -72.52% | -6.83% |
| 1-year return | -71.83% | +15.06% |
| 5-year return | — | -83.51% |
| EPS (TTM) | $-0.07 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $2.61 |
| 52-week low | $3.27 | $1.33 |
| Distance from 52-week high | -77.00% | -26.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +617.84% | +214.14% |
| Average volume | 468.83K | 656.02K |
| Shares outstanding | 80.17M | 139.54M |
| Employees | 88 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed BBOT by 86.9 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
BBOT vs IKT FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Inhibikase Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $274.20M compared with $266.51M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, BBOT or IKT?
IKT returned +15.06% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Inhibikase Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BridgeBio Oncology Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Inhibikase Therapeutics.